论文部分内容阅读
目的为缬沙坦的合理应用提供依据。方法选择40例轻中度高血压且血糖接近临界值的患者,随机分成2组,缬沙坦组20人,氨氯地平组20人,两组受试者基线血压、心率、血糖及年龄、性别构成等差异均无显著性(P<0.05)。2组分别服用缬沙坦和氨氯地平治疗3个月,每2周随访1次,测量血压同时兼测血糖水平。结果缬沙坦组比氨氯地平组新发糖尿病的危险性降低,同时胰岛素敏感性升高。结论缬沙坦在抗高血压治疗中具有其他药物无法替代的优势,可改善糖代谢,预防新发糖尿病;缬沙坦在有效降压的同时具有预防高血压患者新发糖尿病的长期益处。
The purpose is to provide the basis for the reasonable application of valsartan. Methods Forty patients with mild to moderate hypertension and close to the critical blood glucose level were randomly divided into 2 groups: 20 in valsartan group and 20 in amlodipine group. Baseline blood pressure, heart rate, blood glucose and age, Sex composition and other differences were not significant (P <0.05). 2 groups were treated with valsartan and amlodipine for 3 months, followed up every 2 weeks, measuring blood pressure and blood glucose levels. Results The risk of new-onset diabetes in valsartan group was lower than that of amlodipine group, meanwhile insulin sensitivity increased. Conclusion Valsartan has the advantage that other drugs can not be replaced in antihypertensive treatment, which can improve glucose metabolism and prevent new-onset diabetes. Valsartan can effectively reduce the long-term benefits of preventing new-onset diabetes in hypertensive patients.